| Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript |
Celcuity Inc. (NASDAQ:CELC ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Apoorva Chaloori - ICR Healthcare Brian Sullivan - Chief Executive Officer and Co-Founder Vicky Hahne - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Tara Bancroft - TD Cowen Gil Blum - Needham and Company Oliver McCammon - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity First Quarter 2025 Financial Results Webcast Conference Call. At this time all lines are in listen-only mode. |
seekingalpha.com |
2025-05-15 01:36:45 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update |
The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its first patient in the second quarter of 2025 Initiating a clinical trial collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancer Approximately $206 million in cash, cash equivalents and investments at March 31, 2025 is expected to fund current clinical development program activities through 2026 Management to host webcast and conference call today, May 14, 2025, at 4:30 p.m. ET MINNEAPOLIS, May 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the first quarter ended March 31, 2025 and other recent business developments. |
globenewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call |
MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. |
globenewswire.com |
2025-05-07 11:05:00 |
Czytaj oryginał (ang.) |
| Celcuity To Present at Upcoming Needham and Stifel Investor Conferences |
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: |
globenewswire.com |
2025-04-01 11:05:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript |
Celcuity Inc. (NASDAQ:CELC ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Apoorva Chaloori - ICR Healthcare, Investor Relations Brian Sullivan - Co-Founder & Chief Executive Officer Vicky Hahne - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Brad Canino - Stifel Oliver McCammon - LifeSci Capital Gil Blum - Needham Corporation Chase Knickerbocker - Craig-Hallum Capital Group Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year 2024 Financial Results Webcast Conference Call. [Operator Instructions] I would now like to turn the conference over to Apoorva Chaloori with ICR Healthcare. |
seekingalpha.com |
2025-04-01 02:50:26 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter ended December 31, 2024 and other recent business developments. |
globenewswire.com |
2025-03-31 20:01:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call |
MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Monday, March 31, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. |
globenewswire.com |
2025-03-24 09:05:00 |
Czytaj oryginał (ang.) |
| Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences |
MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: |
globenewswire.com |
2025-02-25 09:05:00 |
Czytaj oryginał (ang.) |
| Celcuity's High-Stakes Oncology Bet Is Underappreciated |
Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash position with 13 quarters of runway but faces high R&D expenses and no revenue stream, making it reliant on future funding. Gedatolisib's dual inhibition of PI3K and mTOR may offer a differentiated safety profile and efficacy, potentially capturing market share in breast and prostate cancer. |
seekingalpha.com |
2025-02-19 20:24:09 |
Czytaj oryginał (ang.) |
| Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium |
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months |
globenewswire.com |
2024-12-11 09:05:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. (CELC) Q3 2024 Earnings Call Transcript |
Celcuity Inc. (NASDAQ:CELC ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Apoorva Chaloori - ICR Westwicke, Investor Relations Brian Sullivan - Co-Founder & Chief Executive Officer Vicky Hahne - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Brad Canino - Stifel Tara Bancroft - TD Cowen Chase Knickerbocker - Craig Hallum Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2024 Financial Results Conference Call. At this time, all lines are in listen-only mode. |
seekingalpha.com |
2024-11-14 21:42:28 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update |
MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the third quarter ended September 30, 2024 and other recent business developments. |
globenewswire.com |
2024-11-14 18:01:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences |
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: |
globenewswire.com |
2024-11-12 09:05:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call |
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. |
globenewswire.com |
2024-11-07 09:05:00 |
Czytaj oryginał (ang.) |
| Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings |
On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 1,443,913 shares of Celcuity Inc (NASDAQ: CELC), a clinical-stage biotechnology company. This move reduced their holding by 50.92%, leaving them with 1,391,552 shares. |
gurufocus.com |
2024-10-08 00:11:47 |
Czytaj oryginał (ang.) |
| Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? |
The consensus price target hints at an 87.6% upside potential for Celcuity (CELC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-09-10 14:56:06 |
Czytaj oryginał (ang.) |
| Celcuity (CELC) Upgraded to Buy: Here's Why |
Celcuity (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-08-20 17:00:33 |
Czytaj oryginał (ang.) |
| Celcuity Inc. (CELC) Q2 2024 Earnings Call Transcript |
Celcuity Inc. (NASDAQ:CELC ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 AM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Tara Bancroft - TD Cowen Brad Canino - Stifel Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2024 Financial Results Conference Call. At this time all lines are in listen-only mode. |
seekingalpha.com |
2024-08-16 19:50:26 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update |
MINNEAPOLIS, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the second quarter ended June 30, 2024 and other recent business developments. |
globenewswire.com |
2024-08-14 20:01:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call |
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. |
globenewswire.com |
2024-08-07 11:05:00 |
Czytaj oryginał (ang.) |
| Celcuity: Flying A Phase 3 Trial Right Under Your Nose |
Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks. |
seekingalpha.com |
2024-07-05 04:05:42 |
Czytaj oryginał (ang.) |
| Celcuity To Participate in Jefferies Global Healthcare Conference |
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. |
globenewswire.com |
2024-06-03 20:01:00 |
Czytaj oryginał (ang.) |
| Celcuity Announces Pricing of Underwritten Common Stock Offering |
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share. All of the securities are to be sold by Celcuity. Investors who have agreed to purchase shares in the offering include BVF Partners L.P., a U.S.-based healthcare focused investor, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital Management and Blue Owl Healthcare Opportunities. The offering is expected to close on or about May 31, 2024, subject to satisfaction of customary closing conditions. |
globenewswire.com |
2024-05-30 11:36:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing |
MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer (“ABC”) who are endocrine therapy resistant. In conjunction with its plan to conduct this study, Celcuity today entered into an amendment to an existing debt facility agreement and received an additional term loan of approximately $62 million. |
globenewswire.com |
2024-05-30 11:00:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript |
Celcuity Inc. (NASDAQ:CELC ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Maria Yonkoski - ICR Westwicke, IR Brian Sullivan - Co-Founder and CFO Vicky Hahne - Chief Financial Officer Igor Gorbatchevsky - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Brad Canino - Stifel Gil Blum - Needham & Company Operator Good afternoon, ladies and gentlemen. And welcome the Celcuity First Quarter 2024 Financial Results Conference call. |
seekingalpha.com |
2024-05-15 23:43:05 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update |
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the first quarter ended March 31, 2024 and other recent business developments. |
globenewswire.com |
2024-05-15 20:01:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call |
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. |
globenewswire.com |
2024-05-08 11:05:00 |
Czytaj oryginał (ang.) |
| Celcuity To Present at Upcoming Needham and Stifel Investor Conferences |
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: |
globenewswire.com |
2024-04-04 11:05:00 |
Czytaj oryginał (ang.) |
| Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript |
Celcuity Inc. (CELC) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-27 20:40:09 |
Czytaj oryginał (ang.) |